Eli Lilly may not have discovered orexins, but the pharma’s latest acquisition marks increasing momentum for a drug class that’s maturing after years of fine-tuning. The big question on the minds of Wall Street is whether orexins’ potential is fully known. Lilly announced last week that it was buying Centessa Pharmaceuticals for $6.3 billion upfront, its largest acquisition since it bought Loxo Oncology in 2019, should the deal close. But what if narcolepsy is just scratching the surface? Interviews with Wall Street analysts suggest that’s a possibility, and with Lilly in control, a lot more money could be poured into widening the drugs’ development scope.
Read the full article: Eli Lilly’s Latest Acquisition Could Preview Another Booming Market //
Source: https://endpoints.news/did-eli-lilly-just-strike-another-gold-mine/